Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS)

Reproductive Sciences

Volumn 16, Issue 10, 2009, Pages 938-946

  Aubuchon, Mira ^a   Lieman, Harry ^a,c   Stein, Daniel ^b   Cohen, Hillel W ^b   Isaac, Barbara ^a   Adel, Goli ^a   Weitzman, Vanessa ^c,d   Tetrokalashvili, Maggie ^e   Polotsky, Alex J ^a   Santoro, Nanette ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Department of Endocrinology ^*  (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d IVF Florida Reproductive Associates   (United States)

^e Nassau Health Care Corporation   (United States)

Author keywords

FSH; Insulin resistance; Metformin; Ovulation.; PCOS

Indexed keywords

ANDROGEN; ESTRADIOL; FATTY ACID; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HUMAN INSULIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; METFORMIN; PLACEBO; PREGNANEDIOL; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE; HUMAN; MORBID OBESITY; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; OVULATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LIPID METABOLISM; METABOLOME; METFORMIN; POLYCYSTIC OVARY SYNDROME; REPRODUCTION; YOUNG ADULT;

EID: 70349287732     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719109340925     Document Type: Article

References (35)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M., Waggoner W., Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern united states: a prospective study. J Clin Endocrinol Metab. 1998 ; 83 (9). 3078-3082.
2. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 ; 93 (1). 162-168.
3. Azziz R., Woods KS, Reyna R., Key TJ, Knochenhauer ES, Yildiz BO The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 ; 89 (6). 2745-2749.
4. Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord. 2007 ; 8 (2). 127-141.
5. Waldstreicher J., Santoro NF, Hall JE, Filicori M., Crowley WF Jr. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab. 1988 ; 66 (1). 165-172.
6. Zumoff B., Freeman R., Coupey S., Saenger P., Markowitz M., Kream J. A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome. N Engl J Med. 1983 ; 309 (20). 1206-1209.
7. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C., Quintero N., Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998 ; 83 (6). 2001-2005.
8. Lord JM, Flight IH, Norman RJ Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003 ;(3). CD003053.
9. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998 ; 338 (26). 1876-1880.
10. Nestler JE, Jakubowicz DJ Decreases in ovarian cytochrome P450c17{alpha} activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996 ; 335 (9). 617-623.
11. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991 ; 72 (1). 83-89.
12. Shadid S., Kanaley J., Sheehan M., Jensen M. Basal and insulin-regulated free fatty acid and glucose metabolism in humans. Am J Physiol Endocrinol Metab. 2007 ; 292 (6). E1770-1774.
13. Al Majali K., Cooper MB, Staels B., Luc G., Taskinen MR, Betteridge DJ The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia. 2006 ; 49 (3). 527-537.
14. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific ; 1992: 377-384.
15. Hatch R., Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981 ; 140: 815-830.
16. Alberti KG, Zimmet PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998 ; 15 (7). 539-553.
17. Diamond MP, Jacob R., Connolly-Diamond M., DeFronzo RA Glucose metabolism during the menstrual cycle. Assessment with the euglycemic, hyperinsulinemic clamp. J Reprod Med. 1993 ; 38 (6). 417-421.
18. Thornton KL, DeFronzo RA, Sherwin RS, Diamond MP Micronized estradiol and progesterone: effects on carbohydrate metabolism in reproductive-age women. J Soc Gynecol Investig. 1995 ; 2 (4). 643-652.
19. Saketos M., Sharma N., Adel T., Raghuwanshi M., Santoro N. Time-resolved immunofluorometric assay and specimen storage conditions for measuring urinary gonadotropins. Clin Chem. 1994 ; 40 (5). 749-753.
20. Santoro N., Brown J., Adel T., Skurnick J. Characterization of reproductive hormonal dynamics in the perimenopause. Journal of Clinical Endocrinology & Metabolism. 1996 ; 81 (4). 1495-1501.
21. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci. 1959 ; 82: 420-430.
22. Bier DM, Arnold KJ, Sherman WR, Holland WH, Holmes WF, Kipnis DM In-vivo measurement of glucose and alanine metabolism with stable isotopic tracers. Diabetes. 1977 ; 26 (11). 1005-1015.
23. Brown JB Pituitary control of ovarian function-concepts derived from gonadotrophin therapy. Aust N Z J Obstet Gynaecol. 1978 ; 18 (1). 46-54.
24. Diamanti-Kandarakis E., Kouli C., Tsianateli T., Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998 ; 138 (3). 269-274.
25. Glueck CJ, Wang P., Fontaine R., Tracy T., Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism. 1999 ; 48 (4). 511-519.
26. Nestler JE, Jakubowicz DJ Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab. 1997 ; 82 (12). 4075-4079.
27. Lord J., Thomas R., Fox B., Acharya U., Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome- a randomised, double-blind, placebo-controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2006 ; 113 (7). 817-824.
28. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007 ; 356 (6). 551-566.
29. Ehrmann DA, Cavaghan MK, Imperial J., Sturis J., Rosenfield RL, Polonsky KS Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 ; 82 (2). 524-530.
30. Acbay O., Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome ? Fertil Steril. 1996 ; 65 (5). 946-949.
31. Palomba S., Falbo A., Orio Jr F., Tolino A., Zullo F. Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome. Fertility and Sterility. In Press.
32. Maciel GAR, Soares J°nior JM, Alves da Motta, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril. 2004 ; 81 (2). 355-360. May 9, 2009. http://journals.ohiolink.edu/ejc/article.cgi?issn=00150282&issue= v81i0002&article=355-nwwposowttwm.
33. Moghetti P., Castello R., Negri C., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000 ; 85 (1). 139-146.
34. Srinivasan S., Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006 ; 91 (6). 2074-2080.
35. Morel Y., Golay A., Perneger T., et al. Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Diabetic Med. 1999 ; 16 (8). 650-655.